BioStock: Sprint Bioscience maintains focus on developing the portfolio
With the activities for 2022 in full swing, Sprint Bioscience publishes the report for the year’s first quarter where we can note a continued focus on developing the programs in the portfolio. The company will begin presenting the latest internal program in the portfolio to potential partners and a scientific council has been appointed to support the future development. BioStock contacted the company’s CEO Erik Kinnman to get his thoughts on the first quarter.Read the full article at biostock.se:https://www.biostock.se/en/2022/05/sprint-bioscience-maintains-focus-on-developing-the-